TRIPLE NEGATIVE BREAST NEOPLASMS

This early-stage study is testing a new drug called BT8009 in people with advanced solid tumors that have a specific marker called Nectin-4. The main goals are to find a safe dose, see how the body processes the drug, and get a first look at whether it can shrink tumors. The drug…

This large Phase 3 study is testing whether adding the experimental drug capivasertib to standard paclitaxel chemotherapy works better than paclitaxel alone for advanced triple-negative breast cancer. It involves 923 patients with inoperable or spreading cancer who haven't had pr…

This study is testing several new combinations of immunotherapy and chemotherapy drugs for patients with advanced triple-negative breast cancer that has spread. The goal is to find treatments that better control the cancer and help patients live longer. Researchers will enroll ab…

This study is testing whether adding the oral chemotherapy drug capecitabine to standard carboplatin-based chemotherapy improves outcomes for patients with early triple negative breast cancer before surgery. The main goal is to see if this combination helps more patients achieve …

This is an early-stage study to find a safe dose of a new drug called KFA115, given alone or with an existing immunotherapy (pembrolizumab), for people with advanced cancers that have stopped responding to standard treatments. The main goal is to check for side effects and determ…

This study tested whether adding the drug alpelisib to standard chemotherapy could better control advanced triple-negative breast cancer in patients with specific genetic changes in their tumors. It involved 137 patients and was a Phase 3 trial, but recruitment was halted early. …